MLL-menin and FLT3 inhibitors team up for AML

Abstract

In this issue of Blood1 Dzama and colleagues demonstrate that inhibiting MLL binding to menin synergizes with FLT3 inhibition in preclinical models of NPM1c and KMT2A (MLL)-rearranged AML, thus identifying a novel, rational combination for clinical development.